---
document_datetime: 2025-10-20 16:22:35
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/imvanex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: imvanex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.5473442
conversion_datetime: 2025-12-30 10:47:00.929738
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## IMVANEX

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type IB /  | C.I HUMAN AND VETERINARY MEDICINAL | 16/10/2025                          |                                             | SmPC,                            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000291496                        | PRODUCTS - C.I.z Other variation - Accepted C.I.z - to update the appearance description of the vaccine in Section 3 Pharmaceutical form and in Section 6.6 Special precautions for disposal and other handling of the SmPC to provide a better guidance for the end user. Section 6 of the Package Leaflet was updated accordingly. The MAH took the opportunity to correct a typo in the MAH address (changing All√© to Alle) in section 7 of the SmPC, section 11 of the Labelling and section 6 of the PL and to remove the MAH contact details in section 6 of the PL.   |            | Labelling and PL   |
|------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|--------------------|
| Variation type IA_IN / EMA/VR/0000290088 | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted                                          | 04/08/2025 |                    |

<div style=\"page-break-after: always\"></div>

|                                       | B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.a Tightening of specification limits for medicinal products subject to Official Control Authority Batch Release - Accepted                                                                                                                                                                            |            |     |          |                                                                                                                                                                                                                                                   |
|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000273911 | C.I.11 Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Change in due date for category 1, 2 or 3 studies in the RMP and/or Annex II - Accepted C.I.11.z - To postpone the SOB-004 (A Phase 2 Randomised, Open-Label, Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for mpox) due date from 30-May-2025 to 28- Nov-2025 and to update Annex II of the PI accordingly | 16/06/2025 |     | Annex II | To postpone the SOB-004 (A Phase 2 Randomised, Open-Label, Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for mpox) due date from 30-May-2025 to 28-Nov-2025 and to update Annex II of the PI accordingly |
| Variation type II / EMA/VR/0000256760 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.d Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological                                                                                                                                                                                                      | 15/05/2025 | N/A |          |                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                                       | reagent for a biological active substance - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |            |     |             |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------|
| Variation type IA / EMA/VR/0000261314 | This was an application for a group of variations. B.II.c.1 Change in the specification parameters and/or limits of an excipient - B.II.c.1.a Tightening of specification limits - Accepted B.I.b.1 Change in the specification parameters and/or limits of an active substance, starting material / intermediate / reagent used in the manufacturing process of the active substance - B.I.b.1.b Tightening of specification limits - Accepted B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.a Minor changes to an approved test procedure - Accepted | 25/03/2025 | N/A |             |
| PSUR / EMA/PSUR/0000269020            | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |            |     | Maintenance |